0 309

Cited 4 times in

Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma

Authors
 Seung Min Hahn  ;  Hyo Sun Kim  ;  Dong Joon Kim  ;  Sung Chul Lee  ;  Chuhl Joo Lyu  ;  Jung Woo Han 
Citation
 PEDIATRIC HEMATOLOGY AND ONCOLOGY, Vol.33(1) : 74-82, 2016 
Journal Title
 PEDIATRIC HEMATOLOGY AND ONCOLOGY 
ISSN
 0888-0018 
Issue Date
2016
MeSH
Child, Preschool ; Eye Neoplasms/classification ; Eye Neoplasms/drug therapy* ; Female ; Humans ; Infant ; Male ; Retinoblastoma/classification ; Retinoblastoma/drug therapy*
Keywords
Chemotherapy ; infusions ; intra-arterial ; retinoblastoma
Abstract
The recent trend of treatment for retinoblastoma is to salvage the eye globes as well as achieving patients' survival. Intra-arterial chemotherapy (IAC) is one of the current standard treatment; however, it cannot exclude the risk of occult micrometastases in the central nervous system in advanced-stage retinoblastoma. Alternate fashion of intravenous chemotherapy (IVC) and IAC strategy was developed to increase the eye salvage rate and to reduce the metastatic risk. Between January 2012 and December 2014, 13 eyes of 12 patients with newly diagnosed retinoblastoma received alternate chemotherapy using IVC and IAC in Yonsei Cancer Center. Eye salvage rate was assessed by the eye preservation time, which was defined as the duration from the diagnosis to the time of enucleation. Total 13 eyes were classified according to the International Classification of Retinoblastoma (ICRB) as group B (n = 1, 7.7%), group C (n = 2, 15.4%), group D (n = 5, 38.5%), or group E (n = 5, 38.5%). IAC was performed, 3 to 5 times (median: 4 times) for each eye, total 54 times. Five to 15 courses (median: 8 courses) of systemic chemotherapy were performed in the patients. During the median follow-up period of 30.4 months, overall eye salvage rate was 63.9 ± 14.7%. All patients survived. The treatment was tolerable without significant complications. These results showed that primary alternate IVC-IAC was tolerable and effective for retinoblastoma.
Full Text
http://www.tandfonline.com/doi/abs/10.3109/08880018.2015.1135363
DOI
10.3109/08880018.2015.1135363
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Dong Joon(김동준) ORCID logo https://orcid.org/0000-0002-7035-087X
Lyu, Chuhl Joo(유철주) ORCID logo https://orcid.org/0000-0001-7124-7818
Lee, Sung Chul(이성철) ORCID logo https://orcid.org/0000-0001-9438-2385
Hahn, Seung Min(한승민) ORCID logo https://orcid.org/0000-0001-9832-6380
Han, Jung Woo(한정우) ORCID logo https://orcid.org/0000-0001-8936-1205
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/146745
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse